Cue Biopharma Reports Confirmed Partial Response (PR) in Ongoing Phase 1 Monotherapy Study of CUE-101 in Late Stage Second Line and Beyond Patients with HPV+ Recurrent/Metastatic Head and Neck Cancer

NEXT STORY
Trauma Awareness Month: Online Platform Psychable Connect Those Seeking Legal Psychedelic Assisted Therapy Treatments With Practitioners
PREV STORY
Arch Therapeutics’ AC5® Advanced Wound System Presents with Recognition at the 2021 Symposium on Advanced Wound Care (SAWC) Spring | Wound Healing Society (WHS)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

The Endocrinology Drugs Market is expected to grow by USD 24.78 bn during 2020-2024, progressing at a CAGR of 7% during the forecast period

author_avatar
NASDAQ Market News

RedHill Biopharma Announces Additional Data from Positive Phase III Study of RHB-104 in Crohn’s Disease at United European Gastroenterology (UEG) Week 2018

The presentation highlighted enhanced p-values for previously reported outcomes, including the primary endpoint of ...

author_avatar
NASDAQ Market News

Hemispherx Biopharma Management Team: Reflects Company’s Aggressive Commitment to Strategies Designed to Reach Commercial Goals, Preserve Financial Capital, and Increase Stockholder Value

PHILADELPHIA, Feb. 22, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” ...

author_avatar
NASDAQ Market News